We are honored to host Carter Keller, Head of GigaGen and Senior Vice President at Grifols, as we delve into the groundbreaking advancements of GIGA-2339, the first recombinant polyclonal drug ...

The FDA has approved tirzepatide (Zepbound) as the first and only medication for obstructive sleep apnea (OSA) in adults with obesity. Clinical trials revealed that tirzepatide achieved an average ...

The US FDA has approved BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 as a first-line therapy for BRAF V600E-mutant metastatic colorectal cancer. The Phase 3 BREAKWATER trial showed ...

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for ...

The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends progression-free survival (PFS) in HR+, HER2+ metastatic breast cancer.

General Inception, a global biotech company igniter, has acquired Enable Medicine, a leader in Artificial Intelligence-driven biological research, in a strategic equity partnership aimed at ...

Novartis announced that its drug Ribociclib (Kisqali®) combined with endocrine therapy (ET) demonstrates a sustained 28.5% reduction in distant recurrence for high-risk HR+/HER2- early breast cancer ...